Immunic, INC Schedule 13G passive stakes

OrbiMed Advisors LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital LLC have filed a Schedule 13G, reporting beneficial ownership of Immunic, Inc. common stock.

Nantahala Capital Management, LLC, along with its managing members, has disclosed beneficial ownership of 7.47% of Immunic, Inc.'s common stock as of June 30, 2026.

Soleus Capital Master Fund, L.P. and associated entities have reported beneficial ownership of 4.9% of Immunic, Inc.'s common stock, including shares issuable upon warrant and pre-funded warrant exercise.

Several entities and an individual have filed an amendment to their Schedule 13G, confirming their beneficial ownership of Immunic, Inc. common stock.

Laurion Capital Management LP and associated individuals report beneficial ownership of 6.06% of Immunic, Inc.'s common stock, including shares issuable from warrants.

Aberdeen Group plc and abrdn Inc. have reported a combined beneficial ownership of 6.05% in IMMUNIC, Inc. common stock.

683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman have filed an exit report indicating they no longer beneficially own more than five percent of IMMUNIC, INC.'s common stock.

Millennium Management and affiliated entities have filed a Schedule 13G reporting a 5.7% beneficial ownership stake in Immunic, Inc.

Avidity Partners Management LP and associated entities have reported a 9.9% beneficial ownership stake in Immunic, Inc. common stock.

Deep Track Capital and its affiliates have reported a significant 8.69% beneficial ownership stake in Immunic, Inc., primarily through common stock, pre-funded warrants, and warrants.

Commodore Capital LP and its affiliates have reported a 9.9% beneficial ownership stake in Immunic, Inc., primarily through warrants.

Trails Edge Capital Partners, LP, along with its affiliates, has reported a passive beneficial ownership of 8.7% in Immunic, Inc., totaling 11,454,000 common shares.

Soleus Capital Master Fund and related entities have reported a 5.5% beneficial ownership stake in Immunic, Inc., including shares from warrants.

Nantahala Capital Management, LLC and its managing members have disclosed an 8.22% beneficial ownership stake in Immunic, Inc., including shares from warrants.

Aberdeen Group plc and abrdn Inc. have reported a beneficial ownership of 6.85% in IMMUNIC, INC.'s common stock.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in IMMUNIC, INC., totaling 12,016,444 shares of common stock.

Alyeska Investment Group, L.P. and its affiliates filed an amendment disclosing a 9.35% beneficial ownership stake in Immunic, Inc., comprising 11,250,000 shares.

Avidity Partners Management LP and related entities filed an Amendment No. 5 to Schedule 13G, reporting a 4.8% passive ownership stake in Immunic, Inc. as of September 30, 2025.

Soleus Private Equity Fund III, L.P., Soleus Capital Master Fund, L.P., and related entities, including Guy Levy, updated their passive beneficial ownership in Immunic, Inc., collectively holding 1.6% of common stock.

Biotechnology Value Fund and its affiliates reported a combined beneficial ownership of 9.99% in Immunic, Inc., including significant warrant holdings.

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, has disclosed a 9.9% beneficial ownership stake in Immunic, Inc., primarily through warrants.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, disclosed a 9.99% beneficial ownership stake in Immunic, Inc. as of June 30, 2025.

Avidity Partners Management LP and related entities have reported a 5.9% beneficial ownership stake in IMMUNIC, INC. common stock.

Adage Capital Management, L.P. and its principals have reported a 9.99% beneficial ownership stake in Immunic, Inc., including shares from warrants.

683 Capital Management, LLC and affiliates have disclosed a 9.9% beneficial ownership stake in Immunic, Inc. through exercisable warrants.

Aberdeen Group plc and its subsidiary abrdn Inc. have reported a beneficial ownership of 8.603% in Immunic, Inc.'s common stock.

Avidity Partners Management LP and related entities, including Michael Gregory, have filed an amended Schedule 13G disclosing a beneficial ownership of 6.6% in Immunic, Inc.'s common stock as of March 31, 2025.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a 1.1% beneficial ownership stake in Immunic, Inc. through an Amendment No. 4 to Schedule 13G filing.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 3.0% beneficial ownership stake in Immunic, Inc. as of December 31, 2024, held for investment purposes in the ordinary course of business.

Avidity Partners Management LP and related entities have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.9% of Immunic, Inc.'s common stock as of December 31, 2024.